‘Big data’ can revolutionize gastroenterology | MDLinx
Gastroenterology is suited to benefit from “big data” because it’s a complex speciality with wide-ranging contributing factors.
Gastroenterology is suited to benefit from “big data” because it’s a complex speciality with wide-ranging contributing factors.
Three years ago, Moderna invested part of its vaccine windfall into a new gene-editing startup, Metagenomi. Now it’s backing out.
The current approval is based on the VOLTAIRE-HCLF clinical trial, which examined the bioavailability of high-concentration (100 mg/mL) and low-concentration (50 mg/mL) formulations of adalimumab-adbm.
AUA 2024 upper tract transitional cell carcinoma, efficacy and safety of padeliporfin vascular targeted photodynamic therapy, low-grade upper tract urothelial carcinoma, ENdoluminal LIGHT activated treatment…
AUA 2024 advanced kidney cancer, synchronous metastatic renal cell carcinoma (mRCC), cytoreductive nephrectomy, metastatic burden reduction.
Sam Chang engages with Josh Meeks to discuss nadofaragene firadenovec’s role in treating BCG-unresponsive bladder cancer. They consider the significance of clinical trials and FDA…
AUA 2024, metatatic renal cell carcinoma (mRCC), Sarcomatoid Features in mRCC, metastatic sarcomatoid renal cell carcinoma (msRCC), Cytoreductive Nephrectomy, Immune Checkpoint Inhibitors (ICI), ipilimumab, nivolumab,…
AUA 2024 telemedicine in urology, use of telehealth could reduce racial and ethnic disparities in prostate cancer care, National Health Interview Survey, prostate cancer.
AUA 2024 non-invasive bladder cancer, phase 1 study of intravesical Fc-optimized anti-CD40 agonist antibody 2141-V11, non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
AUA 2024 prostate cancer detection and screening, results of a comparative analysis of clinician performance versus magnetic resonance imaging (MRI), ultrasound integration for artificial intelligence-based…
A controversial provision of a federal law designed to speed copycat drugs to market and foster competition saved Medicare Part D nearly $15 billion from